Merck KGaA Selects Forest Laboratories As U.S. Partner For Alcohol Addiction Treatment
Lipha S.A., a pharmaceutical subsidiary of Merck KGaA in Lyon, France, expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) within the next few months. Based on European clinical studies, data are believed to meet FDA standards for the evaluation of safety and efficacy of acamprosate.
Alcohol abuse and alcohol addiction affect around 16 million people in the United States, representing the third largest cause of death after heart disease and cancer.
Organizations
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.